NCT05432206View on ClinicalTrials.gov

MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

November 29, 2024

Study Completion Date

November 29, 2024

Conditions

Dementia with Behavioral Disturbance

Interventions

DRUG

Cannabis Sativa Oil

Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.

DRUG

Placebo

Hemp virgin seed oil

Trial Locations (1)

1206

FAHPA, Geneva

All Listed Sponsors

collaborator

University Hospital, Geneva

OTHER

lead

Fondation pour l'accueil et l'hébérement des personnes âgées

OTHER

NCT05432206 - MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva | Biotech Hunter | Biotech Hunter